Comparison of treatment outcomes between first-line chemotherapy with or without bevacizumab for advanced ovarian, fallopian tube, and primary peritoneal cancer (Tohoku gynecologic cancer unit: TGCU-RS001 study).
Shoji T, Takatori E, Nagasawa T, Kagabu M, Baba T, Shigeto T, Matsumura Y, Shimizu D, Terada Y, Seino M, Ohta T, Nagase S, Shigeta S, Tokunaga H, Shimada M, Kaiho-Sakuma M, Furukawa S, Soeda S, Watanabe T, Takahashi F, Yokoyama Y.
Shoji T, et al. Among authors: takatori e.
Int J Clin Oncol. 2022 Dec;27(12):1874-1880. doi: 10.1007/s10147-022-02246-1. Epub 2022 Oct 10.
Int J Clin Oncol. 2022.
PMID: 36214925